<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cancersp</journal-id><journal-title-group><journal-title xml:lang="ru">Южно-Российский онкологический журнал/ South Russian Journal of Cancer</journal-title><trans-title-group xml:lang="en"><trans-title>South Russian Journal of Cancer</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2686-9039</issn><publisher><publisher-name>АНО "Перспективы онкологии"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37748/2686-9039-2024-5-1-3</article-id><article-id custom-type="edn" pub-id-type="custom">KCLJWH</article-id><article-id custom-type="elpub" pub-id-type="custom">cancersp-258</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Сравнительная характеристика ортотопической и гетеротопической моделей in vivo рака молочной железы человека</article-title><trans-title-group xml:lang="en"><trans-title>Evaluation of engraftment and growth dynamics of orthotopic and heterotopic in vivo models of human breast cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ляшенко</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Lyashenko</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ляшенко Инна Сергеевна – аспирант, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>SPIN: 5074-2896, AuthorID: 1165761</p></bio><bio xml:lang="en"><p>Inna S. Lyashenko – PhD student, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>SPIN: 5074-2896, AuthorID: 1165761</p></bio><email xlink:type="simple">m.v.mindar@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8734-9210</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Романова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Romanova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Романова Мария Вадимовна – младший научный сотрудник испытательного лабораторного центра, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-8734-9210" ext-link-type="uri">https://orcid.org/0000-0001-8734-9210</ext-link>, SPIN: 5148-0830, AuthorID: 1032029, Scopus Author ID: 57217235360</p></bio><bio xml:lang="en"><p>Maria V. Romanova – junior researcher at testing Laboratory Center, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-8734-9210" ext-link-type="uri">https://orcid.org/0000-0001-8734-9210</ext-link>, SPIN: 5148-0830, AuthorID: 1032029, Scopus Author ID: 57217235360</p></bio><email xlink:type="simple">m.v.mindar@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0676-0871</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гончарова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Goncharova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гончарова Анна Сергеевна – к.б.н., заведующий испытательного лабораторного центра, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-0676-0871" ext-link-type="uri">https://orcid.org/0000-0003-0676-0871</ext-link>, SPIN: 7512-2039, AuthorID: 553424, Scopus Author ID: 57215862139</p></bio><bio xml:lang="en"><p>Anna S. Goncharova – Cand. Sci. (Biol.), head of testing Laboratory Center, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-0676-0871" ext-link-type="uri">https://orcid.org/0000-0003-0676-0871</ext-link>, SPIN: 7512-2039, AuthorID: 553424, Scopus Author ID: 57215862139</p></bio><email xlink:type="simple">fateyeva_a_s@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3753-4463</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ходакова</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khodakova</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ходакова Дарья Владиславовна – младший научный сотрудник испытательного лабораторного центра, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-3753-4463" ext-link-type="uri">https://orcid.org/0000-0003-3753-4463</ext-link>, SPIN: 8718-3983, AuthorID: 1056414, Scopus Author ID: 57221463056</p></bio><bio xml:lang="en"><p>Daria V. Khodakova – junior researcher at testing Laboratory Center, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0003-3753-4463" ext-link-type="uri">https://orcid.org/0000-0003-3753-4463</ext-link>, SPIN: 8718-3983, AuthorID: 1056414, Scopus Author ID: 57221463056</p></bio><email xlink:type="simple">coctail.moxuto@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7823-3865</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Галина</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Galina</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Галина Анастасия Владимировна – младший научный сотрудник испытательного лабораторного центра, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-7823-3865" ext-link-type="uri">https://orcid.org/0000-0001-7823-3865</ext-link>, SPIN: 9171-4476, AuthorID: 1071933, Scopus Author ID: 57221460594</p></bio><bio xml:lang="en"><p>Anastasia V. Galina – junior researcher at testing Laboratory Center, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0001-7823-3865" ext-link-type="uri">https://orcid.org/0000-0001-7823-3865</ext-link>, SPIN: 9171-4476, AuthorID: 1071933, Scopus Author ID: 57221460594</p></bio><email xlink:type="simple">volkovaav58@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9747-8515</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гурова</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gurova</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гурова Софья Валерьевна – младший научный сотрудник испытательного лабораторного центра, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-9747-8515" ext-link-type="uri">https://orcid.org/0000-0002-9747-8515</ext-link>, SPIN: 5413-6901, AuthorID: 1147419</p></bio><bio xml:lang="en"><p>Sofya V. Gurova – junior researcher at testing Laboratory Center, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-9747-8515" ext-link-type="uri">https://orcid.org/0000-0002-9747-8515</ext-link>, SPIN: 5413-6901, AuthorID: 1147419</p></bio><email xlink:type="simple">gurova.sophie@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4558-5896</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Филиппова</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Filippova</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Филиппова Светлана Юрьевна – научный сотрудник лаборатории клеточных технологий, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-4558-5896" ext-link-type="uri">https://orcid.org/0000-0002-4558-5896</ext-link>, SPIN: 9586-2785, AuthorID: 878784, Scopus Author ID: 57189618843</p></bio><bio xml:lang="en"><p>Svetalna Yu. Filippova – researcher, laboratory of cell technologies, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-4558-5896" ext-link-type="uri">https://orcid.org/0000-0002-4558-5896</ext-link>, SPIN: 9586-2785, AuthorID: 878784, Scopus Author ID: 57189618843</p></bio><email xlink:type="simple">filsv@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шатова</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Shatova</surname><given-names>Yu. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шатова Юлиана Сергеевна – д.м.н., ведущий научный сотрудник отдела опухолей мягких тканей и костей, ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации, г. Ростов-на-Дону, Российская Федерация</p><p>SPIN: 8503-3573, AuthorID: 294376</p></bio><bio xml:lang="en"><p>Yuliana S. Shatova – Dr. Sci. (Med.), leading researcher, Department of Soft Tissue and Bone Tumors, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation</p><p>SPIN: 8503-3573, AuthorID: 294376</p></bio><email xlink:type="simple">m.v.mindar@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre for Oncology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>21</day><month>02</month><year>2024</year></pub-date><volume>5</volume><issue>1</issue><fpage>25</fpage><lpage>33</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ляшенко И.С., Романова М.В., Гончарова А.С., Ходакова Д.В., Галина А.В., Гурова С.В., Филиппова С.Ю., Шатова Ю.С., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Ляшенко И.С., Романова М.В., Гончарова А.С., Ходакова Д.В., Галина А.В., Гурова С.В., Филиппова С.Ю., Шатова Ю.С.</copyright-holder><copyright-holder xml:lang="en">Lyashenko I.S., Romanova M.V., Goncharova A.S., Khodakova D.V., Galina A.V., Gurova S.V., Filippova S.Y., Shatova Y.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.cancersp.com/jour/article/view/258">https://www.cancersp.com/jour/article/view/258</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Оценка приживления и динамики роста ксенографтов рака молочной железы (РМЖ) при ортотопической и подкожной инъекции с использованием различных типов биологического материала, а также разработка адекватной модели РМЖ для дальнейших исследований.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Использовали дезагрегированный фрагмент опухоли, полученной от пациентки, паспортизированную клеточную линию РМЖ ВТ20 – карцинома молочной железы человека; первичную клеточную линию карциномы молочной железы человека. В качестве животных-реципиентов использовали самок иммунодефицитных мышей линии Balb/c Nude в количестве 36 голов. В работе были разработаны подкожные и ортотопические модели РМЖ. Наблюдали рост опухоли в течение 28 суток с момента инъекции и осуществляли замеры опухолевых узлов 2 раза в неделю до конца эксперимента. Результаты оценивали с использованием медианы и процентилей. Для оценки достоверности различий использовали непараметрический критерий Манна-Уитни.</p></sec><sec><title>Результаты</title><p>Результаты. В ходе данной работы была определена динамика роста опухолевых узлов при инъекции в различные сайты. Наиболее успешной, при подкожной инъекции, являлась инъекция опухолевых клеток, паспортизированной линии ВТ20. На момент окончания эксперимента медиана опухолевых узлов данной группы составила 100,32 мм³. При анализе динамики роста опухоли при ортотопической инъекции опухолевого материала было выявлено, что в медиана объема опухолевых узлов в группе с паспортизированной культурой клеток ВТ20 и первичной культурой клеток достигала сходных значений – 149,22 и 148,25 мм³. Было выявлено, что как при инъекции клеточных линий, так и клеточной суспензии опухолевые узлы достигали значимо большего объема при ортотопической инъекции.</p></sec><sec><title>Заключение</title><p>Заключение. Нами была получена опухолевая модель РМЖ при различных способах имплантации материала и с возможностью дальнейшего использования при тестировании новых фармакологических субстанций.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose of the study</title><p>Purpose of the study. This work was to assess the engraftment and growth dynamics of breast cancer xenografts during orthotopic and subcutaneous injection using various types of biological material, as well as to develop an adequate model of breast cancer for further research.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We used a disaggregated fragment of a tumor obtained from the patient, a certified breast cancer cell line VT20 – human breast carcinoma; a primary human breast carcinoma cell line. Female immunodeficient mice of the Balb/c Nude line in the amount of 36 animals were used as recipient animals. The subcutaneous and orthotopic models of breast cancer were developed in this project. Tumor growth was observed for 28 days from the moment of injection and tumor nodes were measured 2 times a week until the end of the experiment. Results were assessed using medians and percentiles. The nonparametric Mann-Whitney test was used to assess the significance of differences.</p></sec><sec><title>Results</title><p>Results. The dynamics of the growth of tumor cells when injected into various sites was determined in the process of this work. The most successful in terms of a subcutaneous injection was the injection of tumor cells of the certified VT20 line. By the end of the experiment, the median tumor node of this group was 100.32 mm³. The analysis revealed tumor dynamics with orthotopic injection of tumor material, and the median volume of the tumor node in the group with the passport culture cell VT20 and the primary culture cell reached the same value – 149.22 and 148.25. mm³. It was found that both the cell line and the cell suspension were injected into tumor nodes that reached a significantly larger volume when injected orthotopically.</p></sec><sec><title>Conclusion</title><p>Conclusion. We have obtained a tumor model of breast cancer using various methods of material implantation and with the possibility of further use in testing new pharmacological substances.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>ксенографт</kwd><kwd>Balb/c Nude</kwd><kwd>карцинома</kwd><kwd>ВТ20</kwd><kwd>первичная опухоль</kwd><kwd>клеточная линия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>xenograft</kwd><kwd>Balb/c Nude</kwd><kwd>carcinoma</kwd><kwd>VT20</kwd><kwd>primary tumor</kwd><kwd>cell line</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Шахзадова А. О., Старинский В. В., Лисичникова И. В. Состояние онкологической помощи населению России в 2022 году. Сибирский онкологический журнал. 2023;22(5):5–13. https://doi.org/10.21294/1814-4861-2023-22-5-5-13, EDN: PESHHL</mixed-citation><mixed-citation xml:lang="en">Shakhzadova AO, Starinsky VV, Lisichnikova IV. Cancer care to the population of Russia in 2022. Siberian journal of oncology. 2023;22(5):5–13. (In Russ.). https://doi.org/10.21294/1814-4861-2023-22-5-5-13, EDN: PESHHL</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Zeng L, Li W, Chen CS. Breast cancer animal models and applications. Zool Res. 2020 Sep 18;41(5):477–494. https://doi.org/10.24272/j.issn.2095-8137.2020.095</mixed-citation><mixed-citation xml:lang="en">Zeng L, Li W, Chen CS. Breast cancer animal models and applications. Zool Res. 2020 Sep 18;41(5):477–494. https://doi.org/10.24272/j.issn.2095-8137.2020.095</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lee RS, Sad K, Fawwal DV, Spangle JM. Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response. Cancers (Basel). 2023 Aug 7;15(15):4005. https://doi.org/10.3390/cancers15154005</mixed-citation><mixed-citation xml:lang="en">Lee RS, Sad K, Fawwal DV, Spangle JM. Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response. Cancers (Basel). 2023 Aug 7;15(15):4005. https://doi.org/10.3390/cancers15154005</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rajagopal K, Kalusalingam A, Bharathidasan AR, Sivaprakash A, Shanmugam K, Sundaramoorthy M, et al. In Silico Drug Design of Anti-Breast Cancer Agents. Molecules. 2023 May 18;28(10):4175. https://doi.org/10.3390/molecules28104175</mixed-citation><mixed-citation xml:lang="en">Rajagopal K, Kalusalingam A, Bharathidasan AR, Sivaprakash A, Shanmugam K, Sundaramoorthy M, et al. In Silico Drug Design of Anti-Breast Cancer Agents. Molecules. 2023 May 18;28(10):4175. https://doi.org/10.3390/molecules28104175</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chan J, Wang X, Turner JA, Baldwin NE, Gu J. Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing. Bioinformatics. 2019 Aug 15;35(16):2818–2826. https://doi.org/10.1093/bioinformatics/btz006</mixed-citation><mixed-citation xml:lang="en">Chan J, Wang X, Turner JA, Baldwin NE, Gu J. Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing. Bioinformatics. 2019 Aug 15;35(16):2818–2826. https://doi.org/10.1093/bioinformatics/btz006</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ma J, Wang J, Ghoraie LS, Men X, Haibe-Kains B, Dai P. A Comparative Study of Cluster Detection Algorithms in Protein-Protein Interaction for Drug Target Discovery and Drug Repurposing. Front Pharmacol. 2019;10:109. https://doi.org/10.3389/fphar.2019.00109</mixed-citation><mixed-citation xml:lang="en">Ma J, Wang J, Ghoraie LS, Men X, Haibe-Kains B, Dai P. A Comparative Study of Cluster Detection Algorithms in Protein-Protein Interaction for Drug Target Discovery and Drug Repurposing. Front Pharmacol. 2019;10:109. https://doi.org/10.3389/fphar.2019.00109</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou H, Liu H, Yu Y, Yuan X, Xiao L. Informatics on Drug Repurposing for Breast Cancer. Drug Des Devel Ther. 2023;17:1933– 1943. https://doi.org/10.2147/DDDT.S417563</mixed-citation><mixed-citation xml:lang="en">Zhou H, Liu H, Yu Y, Yuan X, Xiao L. Informatics on Drug Repurposing for Breast Cancer. Drug Des Devel Ther. 2023;17:1933– 1943. https://doi.org/10.2147/DDDT.S417563</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Centonze M, Di Conza G, Lahn M, Fabregat I, Dituri F, Gigante I, et al. Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models. J Exp Clin Cancer Res. 2023 Aug 8;42(1):197. https://doi.org/10.1186/s13046-023-02780-4</mixed-citation><mixed-citation xml:lang="en">Centonze M, Di Conza G, Lahn M, Fabregat I, Dituri F, Gigante I, et al. Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models. J Exp Clin Cancer Res. 2023 Aug 8;42(1):197. https://doi.org/10.1186/s13046-023-02780-4</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gao X, Yourick JJ, Sprando RL. Toxicological applications of human induced pluripotent stem cell-derived hepatocyte-like cells: an updated review. J Toxicol Sci. 2023;48(8):441–456. https://doi.org/10.2131/jts.48.441</mixed-citation><mixed-citation xml:lang="en">Gao X, Yourick JJ, Sprando RL. Toxicological applications of human induced pluripotent stem cell-derived hepatocyte-like cells: an updated review. J Toxicol Sci. 2023;48(8):441–456. https://doi.org/10.2131/jts.48.441</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fernández A, Viaplana C, et al. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Res. 2022 Apr 15;82(8):1646–1657. https://doi.org/10.1158/0008-5472.CAN-21-2409</mixed-citation><mixed-citation xml:lang="en">Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fernández A, Viaplana C, et al. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Res. 2022 Apr 15;82(8):1646–1657. https://doi.org/10.1158/0008-5472.CAN-21-2409</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Singhal SS, Garg R, Mohanty A, Garg P, Ramisetty SK, Mirzapoiazova T, et al. Recent Advancement in Breast Cancer Research: Insights from Model Organisms-Mouse Models to Zebrafish. Cancers (Basel). 2023 May 29;15(11):2961. https://doi.org/10.3390/cancers15112961</mixed-citation><mixed-citation xml:lang="en">Singhal SS, Garg R, Mohanty A, Garg P, Ramisetty SK, Mirzapoiazova T, et al. Recent Advancement in Breast Cancer Research: Insights from Model Organisms-Mouse Models to Zebrafish. Cancers (Basel). 2023 May 29;15(11):2961. https://doi.org/10.3390/cancers15112961</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Кит С. О., Максимов А. Ю., Гончарова А. С., Колесников Е. Н., Санамянц С. В., Кациева Т. Б. и др. Особенности роста пациентоподобных подкожных и ортотопических ксенографтов кардиоэзофагеального рака человека на иммунодефицитных мышах. Современные проблемы науки и образования. 2020;(2):90. https://doi.org/10.17513/spno.29573, EDN: OWIDSM</mixed-citation><mixed-citation xml:lang="en">Kit SO, Maksimov AYu, Goncharova AS, Kolesnikov EN, Sanamyants SV, Katsieva TB, et al. Growth features of patient-derived subcutaneous and orthotopic xenografts of human cardioesophageal cancer in immunodeficient mice. Modern Problems of Science and Education. 2020;(2):90. (In Russ.). https://doi.org/10.17513/spno.29573, EDN: OWIDSM</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Зибиров Р. Ф., Мозеров С. А. Характеристика клеточного микроокружения опухоли. Онкология. Журнал им. П. А. Герцена. 2018;7(2):67–72. https://doi.org/10.17116/onkolog20187267-72</mixed-citation><mixed-citation xml:lang="en">Zibirov RF, Mozerov SA. Characterization of the tumor cell microenvironment. Oncology. P. A. Herzen Journal. 2018;7(2):67– 72. (In Russ.). https://doi.org/10.17116/onkolog20187267-72</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Chen S, Du Y, Guan XY, Yan Q. The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma. Front Oncol. 2023;13:1204513. https://doi.org/10.3389/fonc.2023.1204513</mixed-citation><mixed-citation xml:lang="en">Chen S, Du Y, Guan XY, Yan Q. The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma. Front Oncol. 2023;13:1204513. https://doi.org/10.3389/fonc.2023.1204513</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Lv N, Li M, Liu M, Wu C. Cancer-associated fibroblasts: tumor defenders in radiation therapy. Cell Death Dis. 2023 Aug 22;14(8):541. doi.org/10.1038/s41419-023-06060-z</mixed-citation><mixed-citation xml:lang="en">Zhang Y, Lv N, Li M, Liu M, Wu C. Cancer-associated fibroblasts: tumor defenders in radiation therapy. Cell Death Dis. 2023 Aug 22;14(8):541. doi.org/10.1038/s41419-023-06060-z</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, et al. Identification of the tumour transition states occurring during EMT. Nature. 2018 Apr;556(7702):463–438. https://doi.org/10.1038/s41586-018-0040-3</mixed-citation><mixed-citation xml:lang="en">Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, et al. Identification of the tumour transition states occurring during EMT. Nature. 2018 Apr;556(7702):463–438. https://doi.org/10.1038/s41586-018-0040-3</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kuburich NA, Sabapathy T, Demestichas BR, Maddela JJ, den Hollander P, Mani SA. Proactive and reactive roles of TGF-β in cancer. Semin Cancer Biol. 2023 Oct;95:120–139. https://doi.org/10.1016/j.semcancer.2023.08.002</mixed-citation><mixed-citation xml:lang="en">Kuburich NA, Sabapathy T, Demestichas BR, Maddela JJ, den Hollander P, Mani SA. Proactive and reactive roles of TGF-β in cancer. Semin Cancer Biol. 2023 Oct;95:120–139. https://doi.org/10.1016/j.semcancer.2023.08.002</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Qin Y, Peng F, Ai L, Mu S, Li Y, Yang C, et al. Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis. Cancer Cell Int. 2021 Jun 12;21(1):310. https://doi.org/10.1186/s12935-021-02004-9</mixed-citation><mixed-citation xml:lang="en">Qin Y, Peng F, Ai L, Mu S, Li Y, Yang C, et al. Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis. Cancer Cell Int. 2021 Jun 12;21(1):310. https://doi.org/10.1186/s12935-021-02004-9</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lindner S, Dahlke K, Sontheimer K, Hagn M, Kaltenmeier C, Barth TFE, et al. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 2013 Apr 15;73(8):2468–2479. https://doi.org/10.1158/0008-5472.CAN-12-3450</mixed-citation><mixed-citation xml:lang="en">Lindner S, Dahlke K, Sontheimer K, Hagn M, Kaltenmeier C, Barth TFE, et al. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 2013 Apr 15;73(8):2468–2479. https://doi.org/10.1158/0008-5472.CAN-12-3450</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X, Li X, Wei H, Liu Y, Li N. Mast cells in colorectal cancer tumour progression, angiogenesis, and lymphangiogenesis. Front Immunol. 2023;14:1209056. https://doi.org/10.3389/fimmu.2023.1209056</mixed-citation><mixed-citation xml:lang="en">Liu X, Li X, Wei H, Liu Y, Li N. Mast cells in colorectal cancer tumour progression, angiogenesis, and lymphangiogenesis. Front Immunol. 2023;14:1209056. https://doi.org/10.3389/fimmu.2023.1209056</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Nail HM, Chiu CC, Leung CH, Ahmed MMM, Wang HMD. Exosomal miRNA-mediated intercellular communications and immunomodulatory effects in tumor microenvironments. J Biomed Sci. 2023 Aug 21;30(1):69. https://doi.org/10.1186/s12929-023-00964-w</mixed-citation><mixed-citation xml:lang="en">Nail HM, Chiu CC, Leung CH, Ahmed MMM, Wang HMD. Exosomal miRNA-mediated intercellular communications and immunomodulatory effects in tumor microenvironments. J Biomed Sci. 2023 Aug 21;30(1):69. https://doi.org/10.1186/s12929-023-00964-w</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Krbal L, Soukup J, Stanislav J, Hanusova V. Derivation and basic characterization of colorectal carcinoma primary cell lines. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Dec;161(4):360–368. https://doi.org/10.5507/bp.2017.040</mixed-citation><mixed-citation xml:lang="en">Krbal L, Soukup J, Stanislav J, Hanusova V. Derivation and basic characterization of colorectal carcinoma primary cell lines. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Dec;161(4):360–368. https://doi.org/10.5507/bp.2017.040</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Тимофеева С. В., Филиппова С. Ю., Ситковская А. О., Гненная Н. В., Межевова И. В., Шамова Т. В. и др. Биоресурсная коллекция клеточных линий и первичных опухолей ФГБУ НМИЦ онкологии Минздрава России. Кардиоваскулярная терапия и профилактика. 2022;21(11):3397. https://doi.org/10.15829/1728-8800-2022-3397</mixed-citation><mixed-citation xml:lang="en">Timofeeva SV, Filippova SYu, Sitkovskaya AO, Gnennaya NV, Mezhevova IV, Shamova TV, et al. Bioresource collection of cell lines and primary tumors of the National Medical Research Center of Oncology of the Ministry of Health of Russia. Cardiovascular Therapy and Prevention. 2022;21(11):3397. (In Russ.). https://doi.org/10.15829/1728-8800-2022-3397</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Janik K, Popeda M, Peciak J, Rosiak K, Smolarz M, Treda C, et al. Efficient and simple approach to in vitro culture of primary epithelial cancer cells. Biosci Rep. 2016 Dec;36(6):e00423. https://doi.org/10.1042/BSR20160208</mixed-citation><mixed-citation xml:lang="en">Janik K, Popeda M, Peciak J, Rosiak K, Smolarz M, Treda C, et al. Efficient and simple approach to in vitro culture of primary epithelial cancer cells. Biosci Rep. 2016 Dec;36(6):e00423. https://doi.org/10.1042/BSR20160208</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Nishikata T, Ishikawa M, Matsuyama T, Takamatsu K, Fukuhara T, Konishi Y. Primary culture of breast cancer: a model system for epithelial-mesenchymal transition and cancer stem cells. Anticancer Res. 2013 Jul;33(7):2867–2873.</mixed-citation><mixed-citation xml:lang="en">Nishikata T, Ishikawa M, Matsuyama T, Takamatsu K, Fukuhara T, Konishi Y. Primary culture of breast cancer: a model system for epithelial-mesenchymal transition and cancer stem cells. Anticancer Res. 2013 Jul;33(7):2867–2873.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Charni-Natan M, Goldstein I. Protocol for Primary Mouse Hepatocyte Isolation. STAR Protoc. 2020 Sep 18;1(2):100086. https://doi.org/10.1016/j.xpro.2020.100086</mixed-citation><mixed-citation xml:lang="en">Charni-Natan M, Goldstein I. Protocol for Primary Mouse Hepatocyte Isolation. STAR Protoc. 2020 Sep 18;1(2):100086. https://doi.org/10.1016/j.xpro.2020.100086</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Damm G, Schicht G, Zimmermann A, Rennert C, Fischer N, Kießig M, et al. Effect of glucose and insulin supplementation on the isolation of primary human hepatocytes. EXCLI J. 2019;18:1071–1091. https://doi.org/10.17179/excli2019-1782</mixed-citation><mixed-citation xml:lang="en">Damm G, Schicht G, Zimmermann A, Rennert C, Fischer N, Kießig M, et al. Effect of glucose and insulin supplementation on the isolation of primary human hepatocytes. EXCLI J. 2019;18:1071–1091. https://doi.org/10.17179/excli2019-1782</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Skarkova V, Krupova M, Vitovcova B, Skarka A, Kasparova P, Krupa P, et al. The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior. Int J Mol Sci. 2019 Sep 18;20(18):4630. https://doi.org/10.3390/ijms20184630</mixed-citation><mixed-citation xml:lang="en">Skarkova V, Krupova M, Vitovcova B, Skarka A, Kasparova P, Krupa P, et al. The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior. Int J Mol Sci. 2019 Sep 18;20(18):4630. https://doi.org/10.3390/ijms20184630</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kapałczyńska M, Kolenda T, Przybyła W, Zajączkowska M, Teresiak A, Filas V, et al. 2D and 3D cell cultures – a comparison of different types of cancer cell cultures. Arch Med Sci. 2018 Jun;14(4):910–919. https://doi.org/10.5114/aoms.2016.63743</mixed-citation><mixed-citation xml:lang="en">Kapałczyńska M, Kolenda T, Przybyła W, Zajączkowska M, Teresiak A, Filas V, et al. 2D and 3D cell cultures – a comparison of different types of cancer cell cultures. Arch Med Sci. 2018 Jun;14(4):910–919. https://doi.org/10.5114/aoms.2016.63743</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Long Y, Xie B, Shen HC, Wen D. Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic. Cells. 2022 Nov 30;11(23):3868. https://doi.org/10.3390/cells11233868</mixed-citation><mixed-citation xml:lang="en">Long Y, Xie B, Shen HC, Wen D. Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic. Cells. 2022 Nov 30;11(23):3868. https://doi.org/10.3390/cells11233868</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
